Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Raggi, MA; Pucci, V; Sabbioni, C; Furlanetto, S; Gerra, G
   Simultaneous determination of plasma catecholamine metabolites (homovanillic acid, 3,4-dihydroxy phenyl acetic acid, 3-methoxy-4-hydroxy-phenylglycol) using liquid chromatography with amperometric detection
   JOURNAL OF SEPARATION SCIENCE
   
   M.A. Raggi et al., "Simultaneous determination of plasma catecholamine metabolites (homovanillic acid, 3,4-dihydroxy phenyl acetic acid, 3-methoxy-4-hydroxy-phenylglycol) using liquid chromatography with amperometric detection", J SEP SCI, 24(4), 2001, pp. 275-281
2. Berlind, A
   Effects of haloperidol and phentolamine on the crustacean cardiac ganglion
   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
   
   A. Berlind, "Effects of haloperidol and phentolamine on the crustacean cardiac ganglion", COMP BIOC C, 130(1), 2001, pp. 85-95
3. Berlind, A
   Monoamine pharmacology of the lobster cardiac ganglion
   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
   
   A. Berlind, "Monoamine pharmacology of the lobster cardiac ganglion", COMP BIOC C, 128(3), 2001, pp. 377-390
4. Smith, RC; Infante, M; Singh, A; Khandat, A
   The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia
   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
   
   R.C. Smith et al., "The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia", IN J NEUROP, 4(3), 2001, pp. 239-250
5. Reitzle, K; Warnke, A; Wewetzer, C; Muller, H
   Agranulocytosis in a schizophrenic child receiving clozapine therapy - clinical picture and therapy. a case report
   ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE
   
   K. Reitzle et al., "Agranulocytosis in a schizophrenic child receiving clozapine therapy - clinical picture and therapy. a case report", Z KIND JUG, 29(2), 2001, pp. 137-143
6. Weigmann, H; Hartter, S; Maehrlein, S; Kiefer, W; Kramer, G; Dannhardt, G; Hiemke, C
   Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography
   JOURNAL OF CHROMATOGRAPHY B
   
   H. Weigmann et al., "Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography", J CHROMAT B, 759(1), 2001, pp. 63-71
7. Llerena, A; Berecz, R; Norberto, MJ; de la Rubia, A
   Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection
   JOURNAL OF CHROMATOGRAPHY B
   
   A. Llerena et al., "Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection", J CHROMAT B, 755(1-2), 2001, pp. 349-354
8. Procyshyn, RM; Flynn, S
   Discharge prescribing practices: Comparing a research ward to general treatment wards
   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
   
   R.M. Procyshyn e S. Flynn, "Discharge prescribing practices: Comparing a research ward to general treatment wards", INT J PSYC, 5(2), 2001, pp. 123-128
9. Horacek, J; Libiger, J; Hoschl, C; Borzova, K; Hendrychova, I
   Clozapine-induced concordant agranulocytosis in monozygotic twins
   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE
   
   J. Horacek et al., "Clozapine-induced concordant agranulocytosis in monozygotic twins", INT J PSYC, 5(1), 2001, pp. 71-73
10. Segman, RH; Heresco-Levy, U; Finkel, B; Goltser, T; Shalem, R; Schlafman, M; Dorevitch, A; Yakir, A; Greenberg, D; Lerner, A; Lerer, B
    Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia
    MOLECULAR PSYCHIATRY
    
    R.H. Segman et al., "Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia", MOL PSYCHI, 6(2), 2001, pp. 225-229
11. Basile, VS; Ozdemir, V; Masellis, M; Meltzer, HY; Lieberman, JA; Potkin, SG; Macciardi, FM; Petronis, A; Kennedy, JL
    Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia
    MOLECULAR PSYCHIATRY
    
    V.S. Basile et al., "Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia", MOL PSYCHI, 6(2), 2001, pp. 230-234
12. Arias, B; Gutierrez, B; Pintor, L; Gasto, C; Fananas, L
    Variability in the 5-MT2A receptor gene is associated with seasonal pattern in major depression
    MOLECULAR PSYCHIATRY
    
    B. Arias et al., "Variability in the 5-MT2A receptor gene is associated with seasonal pattern in major depression", MOL PSYCHI, 6(2), 2001, pp. 239-242
13. Boin, F; Zanardini, R; Pioli, R; Altamura, CA; Maes, M; Gennarelli, M
    Association between-G308A tumor necrosis factor alpha gene polymorphism and schizophrenia
    MOLECULAR PSYCHIATRY
    
    F. Boin et al., "Association between-G308A tumor necrosis factor alpha gene polymorphism and schizophrenia", MOL PSYCHI, 6(1), 2001, pp. 79-82
14. Purdon, SE; Woodward, ND; Flor-Henry, P
    Asymmetrical hand force persistence and neuroleptic treatment in schizophrenia
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY
    
    S.E. Purdon et al., "Asymmetrical hand force persistence and neuroleptic treatment in schizophrenia", J INT NEURO, 7(5), 2001, pp. 606-614
15. Risch, SC; McGurk, S; Horner, MD; Nahas, Z; Owens, SD; Molloy, M; Gilliard, C; Christie, S; Markowitz, JS; DeVane, CL; Mintzer, J; George, MS
    A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates
    NEUROCASE
    
    S.C. Risch et al., "A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates", NEUROCASE, 7(2), 2001, pp. 105-110
16. Emsley, R; Oosthuizen, P; Niehaus, D; Stein, D
    Anxiety symptoms in schizophrenia: the need for heightened clinician awareness
    PRIMARY CARE PSYCHIATRY
    
    R. Emsley et al., "Anxiety symptoms in schizophrenia: the need for heightened clinician awareness", PRIM CARE P, 7(1), 2001, pp. 25-29
17. Gimenez-Roldan, S; Mateo, D; Navarro, E; Gines, MM
    Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis
    PARKINSONISM & RELATED DISORDERS
    
    S. Gimenez-Roldan et al., "Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis", PARKINS R D, 7(2), 2001, pp. 121-127
18. Wolters, EC; Berendse, HW
    Management of psychosis in Parkinson's disease
    CURRENT OPINION IN NEUROLOGY
    
    E.C. Wolters e H.W. Berendse, "Management of psychosis in Parkinson's disease", CURR OP NEU, 14(4), 2001, pp. 499-504
19. Ananth, J; Burgoyne, KS; Gadasalli, R; Aquino, S
    How do the atypical antipsychotics work?
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    
    J. Ananth et al., "How do the atypical antipsychotics work?", J PSYCH NEU, 26(5), 2001, pp. 385-394
20. Gobbi, G; Pulvirenti, L
    Long-term treatment with dozapine in an adult with autistic disorder accompanied by aggressive behaviour
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    
    G. Gobbi e L. Pulvirenti, "Long-term treatment with dozapine in an adult with autistic disorder accompanied by aggressive behaviour", J PSYCH NEU, 26(4), 2001, pp. 340-341
21. Tempier, R; Pawliuk, N
    Influence of novel and conventional antipsychotic medication on subjectivequality of life
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    
    R. Tempier e N. Pawliuk, "Influence of novel and conventional antipsychotic medication on subjectivequality of life", J PSYCH NEU, 26(2), 2001, pp. 131-136
22. Purdon, SE; Malla, A; Labelle, A; Lit, W
    Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    
    S.E. Purdon et al., "Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol", J PSYCH NEU, 26(2), 2001, pp. 137-149
23. Khullar, A; Chue, P; Tibbo, P
    Quetiapine and obsessive-compulsive symptoms (OCS): case report and reviewof atypical antipsychotic-induced OCS
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    
    A. Khullar et al., "Quetiapine and obsessive-compulsive symptoms (OCS): case report and reviewof atypical antipsychotic-induced OCS", J PSYCH NEU, 26(1), 2001, pp. 55-59
24. Tauscher, J; Kapur, S
    Choosing the right dose of antipsychotics in schizophrenia - Lessons from neuroimaging studies
    CNS DRUGS
    
    J. Tauscher e S. Kapur, "Choosing the right dose of antipsychotics in schizophrenia - Lessons from neuroimaging studies", CNS DRUGS, 15(9), 2001, pp. 671-678
25. Russell, JM; Mackell, JA
    Bodyweight gain associated with atypical antipsychotics - Epidemiology andtherapeutic implications
    CNS DRUGS
    
    J.M. Russell e J.A. Mackell, "Bodyweight gain associated with atypical antipsychotics - Epidemiology andtherapeutic implications", CNS DRUGS, 15(7), 2001, pp. 537-551
26. Arranz, MJ; Mancama, D; Kerwin, RW
    Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    
    M.J. Arranz et al., "Neurotransmitter receptor variants and their influence on antipsychotic treatment (Review)", INT J MOL M, 7(1), 2001, pp. 27-30
27. Hirose, S; Ashby, CR; Mills, MJ
    Effectiveness of ECT combined with risperidone against aggression in schizophrenia
    JOURNAL OF ECT
    
    S. Hirose et al., "Effectiveness of ECT combined with risperidone against aggression in schizophrenia", J ECT, 17(1), 2001, pp. 22-26
28. Baillargeon, J; Contreras, SA
    Antipsychotic prescribing patterns in the texas prison system
    JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
    
    J. Baillargeon e S.A. Contreras, "Antipsychotic prescribing patterns in the texas prison system", J AM A PSYC, 29(1), 2001, pp. 48-53
29. Trestman, RL
    Commentary: Antipsychotic prescribing practices in the Texas prison system
    JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
    
    R.L. Trestman, "Commentary: Antipsychotic prescribing practices in the Texas prison system", J AM A PSYC, 29(1), 2001, pp. 54-57
30. Escamilla, M
    Diagnosis and treatment of mood disorders that co-occur with schizophrenia
    PSYCHIATRIC SERVICES
    
    M. Escamilla, "Diagnosis and treatment of mood disorders that co-occur with schizophrenia", PSYCH SERV, 52(7), 2001, pp. 911-919
31. Mellman, TA; Miller, AL; Weissman, EM; Crismon, ML; Essock, SM; Marder, SR
    Evidence-based pharmacologic treatment for people with severe mental illness: A focus on guidelines and algorithms
    PSYCHIATRIC SERVICES
    
    T.A. Mellman et al., "Evidence-based pharmacologic treatment for people with severe mental illness: A focus on guidelines and algorithms", PSYCH SERV, 52(5), 2001, pp. 619-625
32. Noordsy, DL; O'Keefe, C; Mueser, KT; Xie, HY
    Six-month outcomes for patients who switched to olanzapine treatment
    PSYCHIATRIC SERVICES
    
    D.L. Noordsy et al., "Six-month outcomes for patients who switched to olanzapine treatment", PSYCH SERV, 52(4), 2001, pp. 501-507
33. Tang, WK; Ungvari, GS
    Rehab rounds - Electroconvulsive therapy in rehabilitation: The Hong Kong experience
    PSYCHIATRIC SERVICES
    
    W.K. Tang e G.S. Ungvari, "Rehab rounds - Electroconvulsive therapy in rehabilitation: The Hong Kong experience", PSYCH SERV, 52(3), 2001, pp. 303-306
34. Geller, JL
    The case of Sam: Multidisciplinary perspectives
    PSYCHIATRIC SERVICES
    
    J.L. Geller, "The case of Sam: Multidisciplinary perspectives", PSYCH SERV, 52(10), 2001, pp. 1318-1330
35. Osser, DN; Sigadel, R
    Short-term inpatient pharmacotherapy of schizophrenia
    HARVARD REVIEW OF PSYCHIATRY
    
    D.N. Osser e R. Sigadel, "Short-term inpatient pharmacotherapy of schizophrenia", HARV R PSYC, 9(3), 2001, pp. 89-104
36. Salzman, C; Tune, L
    Neuroleptic treatment of late-life schizophrenia
    HARVARD REVIEW OF PSYCHIATRY
    
    C. Salzman e L. Tune, "Neuroleptic treatment of late-life schizophrenia", HARV R PSYC, 9(2), 2001, pp. 77-83
37. Patel, JK; Caplan, B; Green, A; Tamminga, C
    First-episode psychosis: Critical management issues during the first two years
    HARVARD REVIEW OF PSYCHIATRY
    
    J.K. Patel et al., "First-episode psychosis: Critical management issues during the first two years", HARV R PSYC, 9(1), 2001, pp. 33-41
38. Alfaro, CL; McClure, RK; Vertrees, JE; Benavides, R
    Unanticipated plasma concentrations in two clozapine-treated patients
    ANNALS OF PHARMACOTHERAPY
    
    C.L. Alfaro et al., "Unanticipated plasma concentrations in two clozapine-treated patients", ANN PHARMAC, 35(9), 2001, pp. 1028-1031
39. Hoehns, JD; Fouts, MM; Kelly, MW; Tu, KB
    Sudden cardiac death with clozapine and sertraline combination
    ANNALS OF PHARMACOTHERAPY
    
    J.D. Hoehns et al., "Sudden cardiac death with clozapine and sertraline combination", ANN PHARMAC, 35(7-8), 2001, pp. 862-866
40. English, BA; Still, DJ; Harper, J; Saklad, SR
    Failure of tolterodine to treat clozapine-induced nocturnal enuresis
    ANNALS OF PHARMACOTHERAPY
    
    B.A. English et al., "Failure of tolterodine to treat clozapine-induced nocturnal enuresis", ANN PHARMAC, 35(7-8), 2001, pp. 867-869
41. Garcia, G; Ghani, S; Poveda, RA; Dansky, BL
    Neuroleptic malignant syndrome with antidepressant/antipsychotic drug combination
    ANNALS OF PHARMACOTHERAPY
    
    G. Garcia et al., "Neuroleptic malignant syndrome with antidepressant/antipsychotic drug combination", ANN PHARMAC, 35(6), 2001, pp. 784-785
42. Farver, DK; Khan, MH
    Zolpidem for antipsychatic-induced parkinsonism
    ANNALS OF PHARMACOTHERAPY
    
    D.K. Farver e M.H. Khan, "Zolpidem for antipsychatic-induced parkinsonism", ANN PHARMAC, 35(4), 2001, pp. 435-437
43. Sajbel, TA; Carter, GW; Wiley, RB
    Converting patients from brand-name clozapine to generic clozapine
    ANNALS OF PHARMACOTHERAPY
    
    T.A. Sajbel et al., "Converting patients from brand-name clozapine to generic clozapine", ANN PHARMAC, 35(3), 2001, pp. 281-284
44. Zerjav-Lacombe, S; Dewan, V
    Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine
    ANNALS OF PHARMACOTHERAPY
    
    S. Zerjav-Lacombe e V. Dewan, "Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine", ANN PHARMAC, 35(2), 2001, pp. 180-182
45. Avram, AM; Patel, V; Taylor, HC; Kirwan, JP; Kalhan, S
    Euglycemic clamp study in clozapine-induced diabetic ketoacidosis
    ANNALS OF PHARMACOTHERAPY
    
    A.M. Avram et al., "Euglycemic clamp study in clozapine-induced diabetic ketoacidosis", ANN PHARMAC, 35(11), 2001, pp. 1381-1387
46. Albanese, MJ
    Safety and efficacy of risperidone in substance abusers with psychosis
    AMERICAN JOURNAL ON ADDICTIONS
    
    M.J. Albanese, "Safety and efficacy of risperidone in substance abusers with psychosis", AM J ADDICT, 10(2), 2001, pp. 190-191
47. Lisman, JE; Otmakhova, NA
    Storage, recall, and novelty detection of sequences by the hippocampus: Elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine
    HIPPOCAMPUS
    
    J.E. Lisman e N.A. Otmakhova, "Storage, recall, and novelty detection of sequences by the hippocampus: Elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine", HIPPOCAMPUS, 11(5), 2001, pp. 551-568
48. Reuss, B; Unsicker, K
    Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes
    MOLECULAR AND CELLULAR NEUROSCIENCE
    
    B. Reuss e K. Unsicker, "Atypical neuroleptic drugs downregulate dopamine sensitivity in rat cortical and striatal astrocytes", MOL CELL NE, 18(2), 2001, pp. 197-209
49. Spivak, B; Mozes, T; Mester, R; Kodelik, M; Weizman, A
    Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: An open-label study
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
    
    B. Spivak et al., "Zuclopenthixol treatment of behavioral disturbances in mentally retarded children and adolescents: An open-label study", J CH AD PSY, 11(3), 2001, pp. 279-284
50. Domon, SE; Webber, JC
    Hyperglycemia and hypertriglyceridemia secondary to olanzapine
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
    
    S.E. Domon e J.C. Webber, "Hyperglycemia and hypertriglyceridemia secondary to olanzapine", J CH AD PSY, 11(3), 2001, pp. 285-288
51. Parraga, HC; Parraga, MI; Woodward, RL; Fenning, PA
    Quetiapine treatment of children with Tourette's syndrome: Report of two cases
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
    
    H.C. Parraga et al., "Quetiapine treatment of children with Tourette's syndrome: Report of two cases", J CH AD PSY, 11(2), 2001, pp. 187-191
52. Lachar, D; Bailley, SE; Rhoades, HM; Espadas, A; Aponte, M; Cowan, KA; Gummattira, P; Kopecky, CR; Wassef, A
    New subscales for an anchored version of the Brief Psychiatric Rating Scale: Construction, reliability, and validity in acute psychiatric admissions
    PSYCHOLOGICAL ASSESSMENT
    
    D. Lachar et al., "New subscales for an anchored version of the Brief Psychiatric Rating Scale: Construction, reliability, and validity in acute psychiatric admissions", PSYC ASSESS, 13(3), 2001, pp. 384-395
53. Golimbet, VE; Alfimova, MV; Manandyan, KK; Mitushina, NG; Abramova, LI; Kaleda, VG; Oleichik, IV; Yurov, YB; Trubnikov, VI
    Serotonin type 2a (5-HTR2A) receptor gene polymorphism and personality traits in patients with major psychoses
    RUSSIAN JOURNAL OF GENETICS
    
    V.E. Golimbet et al., "Serotonin type 2a (5-HTR2A) receptor gene polymorphism and personality traits in patients with major psychoses", RUSS J GEN, 37(4), 2001, pp. 436-439
54. Matloubi, H; Ghandi, M; Zarrindast, MR; Saemian, N
    Modified synthesis of 11-[C-14]-clozapine
    APPLIED RADIATION AND ISOTOPES
    
    H. Matloubi et al., "Modified synthesis of 11-[C-14]-clozapine", APPL RAD IS, 55(6), 2001, pp. 789-791
55. Scapecchi, S; Marucci, G; Matucci, R; Angeli, P; Bellucci, C; Buccioni, M; Dei, S; Gualtieri, F; Manetti, D; Romanelli, MN; Teodori, E
    Structure-activity relationships in 2,2-diphenyl-2-ethylthioacetic acid esters: Unexpected agonistic activity in a series of muscarinic antagonists
    BIOORGANIC & MEDICINAL CHEMISTRY
    
    S. Scapecchi et al., "Structure-activity relationships in 2,2-diphenyl-2-ethylthioacetic acid esters: Unexpected agonistic activity in a series of muscarinic antagonists", BIO MED CH, 9(5), 2001, pp. 1165-1174
56. Hodgetts, KJ; Kieltyka, A; Brodbeck, R; Tran, JN; Wasley, JWF; Thurkauf, A
    6-(4-benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D-4 receptors
    BIOORGANIC & MEDICINAL CHEMISTRY
    
    K.J. Hodgetts et al., "6-(4-benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D-4 receptors", BIO MED CH, 9(12), 2001, pp. 3207-3213
57. Erbagci, AB; Herken, H; Koyluoglu, O; Yilmaz, N; Tarakcioglu, M
    Serum IL-1 beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment
    MEDIATORS OF INFLAMMATION
    
    A.B. Erbagci et al., "Serum IL-1 beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment", MEDIAT INFL, 10(3), 2001, pp. 109-115
58. Niesler, B; Flohr, T; Nothen, MM; Fischer, C; Rietschel, M; Franzek, E; Albus, M; Propping, P; Rappold, GA
    Association between the 5 ' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder
    PHARMACOGENETICS
    
    B. Niesler et al., "Association between the 5 ' UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder", PHARMACOGEN, 11(6), 2001, pp. 471-475
59. Hong, CJ; Lin, CH; Yu, YWY; Yang, KH; Tsai, SJ
    Genetic variants of the serotonin system and weight change during clozapine treatment
    PHARMACOGENETICS
    
    C.J. Hong et al., "Genetic variants of the serotonin system and weight change during clozapine treatment", PHARMACOGEN, 11(3), 2001, pp. 265-268
60. Dettling, M; Schaub, RT; Mueller-Oerlinghausen, B; Roots, I; Cascorbi, I
    Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry
    PHARMACOGENETICS
    
    M. Dettling et al., "Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry", PHARMACOGEN, 11(2), 2001, pp. 135-141
61. See, RE; Berglind, WJ
    Decreased pallidal GABA following reverse microdialysis with, clozapine, but not haloperidol
    NEUROREPORT
    
    R.E. See e W.J. Berglind, "Decreased pallidal GABA following reverse microdialysis with, clozapine, but not haloperidol", NEUROREPORT, 12(17), 2001, pp. 3655-3658
62. Qiao, H; Noda, Y; Kamei, H; Nagai, T; Furukawa, H; Miura, H; Kayukawa, Y; Ohta, T; Nabeshima, T
    Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment
    NEUROREPORT
    
    H. Qiao et al., "Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment", NEUROREPORT, 12(1), 2001, pp. 11-15
63. Linn, GS; Javitt, DC
    Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys
    NEUROREPORT
    
    G.S. Linn e D.C. Javitt, "Phencyclidine (PCP)-induced deficits of prepulse inhibition in monkeys", NEUROREPORT, 12(1), 2001, pp. 117-120
64. Goudie, AJ; Baker, LE; Smith, JA; Prus, AJ; Svensson, KA; Cortes-Burgos, LA; Wong, EHF; Haadsma-Svensson, S
    Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D-3 preferring antagonist PNU-99194A: an analysis of possible mechanisms
    BEHAVIOURAL PHARMACOLOGY
    
    A.J. Goudie et al., "Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D-3 preferring antagonist PNU-99194A: an analysis of possible mechanisms", BEHAV PHARM, 12(5), 2001, pp. 303-315
65. Shiigi, Y; Casey, DE
    Effects of benztropine on ketamine-induced behaviors in Cebus monkeys
    BEHAVIOURAL PHARMACOLOGY
    
    Y. Shiigi e D.E. Casey, "Effects of benztropine on ketamine-induced behaviors in Cebus monkeys", BEHAV PHARM, 12(4), 2001, pp. 293-298
66. Naidu, PS; Kulkarni, SK
    Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide
    BEHAVIOURAL PHARMACOLOGY
    
    P.S. Naidu e S.K. Kulkarni, "Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide", BEHAV PHARM, 12(3), 2001, pp. 209-216
67. Palmblad, J; Papadaki, HA; Eliopoulos, G
    Acute and chronic neutropenias. What is new?
    JOURNAL OF INTERNAL MEDICINE
    
    J. Palmblad et al., "Acute and chronic neutropenias. What is new?", J INTERN M, 250(6), 2001, pp. 476-491
68. Lipska, BK; Khaing, ZZ; Weickert, CS; Weinberger, DR
    BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs
    EUROPEAN JOURNAL OF NEUROSCIENCE
    
    B.K. Lipska et al., "BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs", EUR J NEURO, 14(1), 2001, pp. 135-144
69. Owen, GS; Halliwell, JV
    Electrophysiological characterization of laminar synaptic inputs to the olfactory tubercle of the rat studied in vitro: modulation of glutamatergic transmission by cholinergic agents is pathway-specific
    EUROPEAN JOURNAL OF NEUROSCIENCE
    
    G.S. Owen e J.V. Halliwell, "Electrophysiological characterization of laminar synaptic inputs to the olfactory tubercle of the rat studied in vitro: modulation of glutamatergic transmission by cholinergic agents is pathway-specific", EUR J NEURO, 13(9), 2001, pp. 1767-1780
70. Ovalle, S; Zamanillo, D; Andreu, F; Farre, AJ; Guitart, X
    Fibroblast growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential sigma-1 receptor ligand and putative atypical antipsychotic
    EUROPEAN JOURNAL OF NEUROSCIENCE
    
    S. Ovalle et al., "Fibroblast growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential sigma-1 receptor ligand and putative atypical antipsychotic", EUR J NEURO, 13(5), 2001, pp. 909-915
71. Hempel, AG; Cormack, TS
    Treatment of the mentally disordered offender
    CURRENT OPINION IN PSYCHIATRY
    
    A.G. Hempel e T.S. Cormack, "Treatment of the mentally disordered offender", CUR OPIN P, 14(6), 2001, pp. 565-569
72. Malhotra, AK
    The genetics of schizophrenia
    CURRENT OPINION IN PSYCHIATRY
    
    A.K. Malhotra, "The genetics of schizophrenia", CUR OPIN P, 14(1), 2001, pp. 3-7
73. Fenton, WS
    Comorbid conditions in schizophrenia
    CURRENT OPINION IN PSYCHIATRY
    
    W.S. Fenton, "Comorbid conditions in schizophrenia", CUR OPIN P, 14(1), 2001, pp. 17-23
74. Barnes, TRE; Joyce, EM
    Antipsychotic drug treatment: recent advances
    CURRENT OPINION IN PSYCHIATRY
    
    T.R.E. Barnes e E.M. Joyce, "Antipsychotic drug treatment: recent advances", CUR OPIN P, 14(1), 2001, pp. 25-37
75. Markianos, M; Hatzimanolis, J; Lykouras, L
    Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    
    M. Markianos et al., "Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol", EUR ARCH PS, 251(3), 2001, pp. 141-146
76. Bernardo, M; Parellada, E; Lomena, F; Catafau, AM; Font, M; Gomez, JC; Lopez-Carrero, C; Gutierrez, F; Pavia, J; Salamero, M
    Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study
    PSYCHIATRY RESEARCH-NEUROIMAGING
    
    M. Bernardo et al., "Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint [I-123]IBZM SPECT study", PSYCH RES-N, 107(2), 2001, pp. 87-97
77. Melkersson, K; Khan, A; Hilding, A; Hulting, AL
    Different effects of antipsychotic drugs on insulin release in vitro
    EUROPEAN NEUROPSYCHOPHARMACOLOGY
    
    K. Melkersson et al., "Different effects of antipsychotic drugs on insulin release in vitro", EUR NEUROPS, 11(5), 2001, pp. 327-332
78. Gefvert, O; Lundberg, T; Wieselgren, IM; Bergstrom, M; Langstrom, B; Wiesel, FA; Lindstrom, L
    D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study
    EUROPEAN NEUROPSYCHOPHARMACOLOGY
    
    O. Gefvert et al., "D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study", EUR NEUROPS, 11(2), 2001, pp. 105-110
79. Schreinzer, D; Frey, R; Stimpfl, T; Vycudilik, W; Berzlanovich, A; Kasper, S
    Different fatal toxicity of neuroleptics identified by autopsy
    EUROPEAN NEUROPSYCHOPHARMACOLOGY
    
    D. Schreinzer et al., "Different fatal toxicity of neuroleptics identified by autopsy", EUR NEUROPS, 11(2), 2001, pp. 117-124
80. Liebzeit, KA; Markowitz, JS; Caley, CF
    New onset diabetes and atypical antipsychotics
    EUROPEAN NEUROPSYCHOPHARMACOLOGY
    
    K.A. Liebzeit et al., "New onset diabetes and atypical antipsychotics", EUR NEUROPS, 11(1), 2001, pp. 25-32
81. Naber, D; Karow, A
    Good tolerability equals good results: the patient's perspective
    EUROPEAN NEUROPSYCHOPHARMACOLOGY
    
    D. Naber e A. Karow, "Good tolerability equals good results: the patient's perspective", EUR NEUROPS, 11, 2001, pp. 391-396
82. Lynch, J; Morrison, J; Graves, N; Meddis, D; Drummond, MF; Hellewell, JSE
    The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia
    EUROPEAN PSYCHIATRY
    
    J. Lynch et al., "The health economic implications of treatment with quetiapine: an audit oflong-term treatment for patients with chronic schizophrenia", EUR PSYCHIA, 16(5), 2001, pp. 307-312
83. Mauri, MC; Laini, V; Boscati, L; Rudelli, R; Salvi, V; Orlandi, R; Papa, P
    Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels
    EUROPEAN PSYCHIATRY
    
    M.C. Mauri et al., "Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels", EUR PSYCHIA, 16(1), 2001, pp. 57-63
84. Huppert, JD; Weiss, KA; Lim, R; Pratt, S; Smith, TE
    Quality of life in schizophrenia: contributions of anxiety and depression
    SCHIZOPHRENIA RESEARCH
    
    J.D. Huppert et al., "Quality of life in schizophrenia: contributions of anxiety and depression", SCHIZOPHR R, 51(2-3), 2001, pp. 171-180
85. Kowalski, J; Blada, P; Kucia, K; Madej, A; Herman, ZS
    Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia
    SCHIZOPHRENIA RESEARCH
    
    J. Kowalski et al., "Neuroleptics normalize increased release of interleukin-1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia", SCHIZOPHR R, 50(3), 2001, pp. 169-175
86. Knott, V; Labelle, A; Jones, B; Mahoney, C
    Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment
    SCHIZOPHRENIA RESEARCH
    
    V. Knott et al., "Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment", SCHIZOPHR R, 50(1-2), 2001, pp. 41-53
87. Ganguli, R; Brar, JS; Ayrton, Z
    Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone
    SCHIZOPHRENIA RESEARCH
    
    R. Ganguli et al., "Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone", SCHIZOPHR R, 49(3), 2001, pp. 261-267
88. Tsai, SJ; Wang, YC; Younger, WYY; Lin, CH; Yang, KH; Hong, CJ
    Association analysis of polymorphism in the promoter region of the alpha 2a-adrenoceptor gene with schizophrenia and clozapine response
    SCHIZOPHRENIA RESEARCH
    
    S.J. Tsai et al., "Association analysis of polymorphism in the promoter region of the alpha 2a-adrenoceptor gene with schizophrenia and clozapine response", SCHIZOPHR R, 49(1-2), 2001, pp. 53-58
89. Frodl, T; Meisenzahl, EM; Muller, D; Greiner, J; Juckel, G; Leinsinger, G; Hahn, H; Moller, HJ; Hegerl, U
    Corpus callosum and P300 in schizophrenia
    SCHIZOPHRENIA RESEARCH
    
    T. Frodl et al., "Corpus callosum and P300 in schizophrenia", SCHIZOPHR R, 49(1-2), 2001, pp. 107-119
90. Rasmussen, T; Fink-Jensen, A; Sauerberg, P; Swedberg, MDB; Thomsen, C; Sheardown, MJ; Jeppesen, L; Calligaro, DO; DeLapp, NW; Whitesitt, C; Ward, JS; Shannon, HE; Bymaster, FP
    The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance
    SCHIZOPHRENIA RESEARCH
    
    T. Rasmussen et al., "The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance", SCHIZOPHR R, 49(1-2), 2001, pp. 193-201
91. Konicki, PE; Kwon, KY; Steele, V; White, J; Fuller, M; Jurjus, GJ; Jaskiw, GE
    Prefrontal cortical sulcal widening associated with poor treatment response to clozapine
    SCHIZOPHRENIA RESEARCH
    
    P.E. Konicki et al., "Prefrontal cortical sulcal widening associated with poor treatment response to clozapine", SCHIZOPHR R, 48(2-3), 2001, pp. 173-176
92. Cuesta, MJ; Peralta, V; Zarzuela, A
    Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study
    SCHIZOPHRENIA RESEARCH
    
    M.J. Cuesta et al., "Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study", SCHIZOPHR R, 48(1), 2001, pp. 17-28
93. Purdon, SE; Labelle, A; Boulay, L
    Neuropsychological change in schizophrenia after 6 weeks of clozapine
    SCHIZOPHRENIA RESEARCH
    
    S.E. Purdon et al., "Neuropsychological change in schizophrenia after 6 weeks of clozapine", SCHIZOPHR R, 48(1), 2001, pp. 57-67
94. Farah, A
    Reduction of tardive dyskinesia with quetiapine
    SCHIZOPHRENIA RESEARCH
    
    A. Farah, "Reduction of tardive dyskinesia with quetiapine", SCHIZOPHR R, 47(2-3), 2001, pp. 309-310
95. Masellis, M; Basile, VS; Meltzer, HY; Lieberman, JA; Sevy, S; Goldman, DA; Hamblin, MW; Macciardi, FM; Kennedy, JL
    Lack of association between the T -> C 267 serotonin 5-MT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia
    SCHIZOPHRENIA RESEARCH
    
    M. Masellis et al., "Lack of association between the T -> C 267 serotonin 5-MT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia", SCHIZOPHR R, 47(1), 2001, pp. 49-58
96. Gjere, NA
    Psychopharmacology in pregnancy
    JOURNAL OF PERINATAL & NEONATAL NURSING
    
    N.A. Gjere, "Psychopharmacology in pregnancy", J PERINAT N, 14(4), 2001, pp. 12-25
97. Wadenberg, MLG; Soliman, A; VanderSpek, SC; Kapur, S
    Dopamine D-2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects
    NEUROPSYCHOPHARMACOLOGY
    
    M.L.G. Wadenberg et al., "Dopamine D-2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects", NEUROPSYCH, 25(5), 2001, pp. 633-641
98. Gur, RC; Ragland, JD; Moberg, PJ; Bilker, WB; Kohler, C; Siegel, SJ; Gur, RE
    Computerized neurocognitive scanning: II. The profile of schizophrenia
    NEUROPSYCHOPHARMACOLOGY
    
    R.C. Gur et al., "Computerized neurocognitive scanning: II. The profile of schizophrenia", NEUROPSYCH, 25(5), 2001, pp. 777-788
99. Scheepers, FE; Wied, CCG; Westenberg, HGM; Kahn, RS
    The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients
    NEUROPSYCHOPHARMACOLOGY
    
    F.E. Scheepers et al., "The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients", NEUROPSYCH, 25(4), 2001, pp. 468-475
100. Audinot, V; Newman-Tancredi, A; Cussac, D; Millan, MJ
     Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT1D receptors
     NEUROPSYCHOPHARMACOLOGY
     
     V. Audinot et al., "Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT1D receptors", NEUROPSYCH, 25(3), 2001, pp. 410-422